1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Recent Upswing Turns Down, But Two Small IPOs Launch

Ocean Biomedical To Go Public Via SPAC Merger

 
• By Mandy Jackson and Jung Won Shin

Shuttle Pharmaceuticals and PaxMedica launch two small initial public offerings in the US as the market awaits a significant IPO. Also, Assertio closed a $70m follow-on offering, Codiak restructures and cuts jobs, and Vilya emerges with $50m in series A venture capital. 

Finance Watch Image
• Source: Shutterstock

Two more small biopharmaceutical companies managed to launch initial public offerings recently, bringing the 2022 total to 17 drug developers that have gone public in the US this year, despite the fact that rising valuation gains earlier in the month were largely wiped out by the end of August.

PaxMedica, Inc. launched its IPO on 26 August, grossing $8.1m from the sale of 1.55 million shares at $5.25...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Finance Watch: Lilly Toes The $1 Trillion Valuation Line

 
• By Mandy Jackson

Public Company Edition: Lilly’s obesity franchise makes it the highest-valued health care company in the US. Also, Genmab accesses $4.5bn to fund its $8bn Merus buy, Moderna locks in a $1.5bn credit facility and Ionis sells $700m worth of notes.

AimedBio IPO Raises Hopes Of Investor Appetite For Korean Biotech

 
• By Jung Won Shin

The success of AimedBio’s IPO may indicate investors are returning to the South Korean biopharma sector amid a series of large global out-licensing deals by domestic ventures and the strong performance of some recent biotech debutants on Kosdaq.

Finance Watch: Poxel Pulls Back From The Brink With Recovery Plan

 
• By Mandy Jackson

Restructuring Edition: Nxera will cut its workforce by 15% in Japan and the UK, among other changes. Also, nearing the end of its cash, Applied Therapeutics cuts 46% of its employees, Korro will cut staffing by 34% as it shifts focus and Metagenomi revealed a 25% workforce reduction.

Five Things To Know From Moderna’s Analyst Day

 
• By Joseph Haas

Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.

More from Business

Sibeprenlimab’s US Accelerated Approval Drives IgAN Competition Forward

 
• By Lisa Takagi

Following US approval of its first-in-class drug for IgAN sibeprelimab, Otsuka is planning an sNDA for an autoinjector in 2026 and is in talks with regulatory authorities in Japan and Europe.

The Rise of China Biopharma – Five Themes In 2025

 
• By Andrew McConaghie

The growth of China’s biopharma sector has been perhaps the most significant sector trend this year – Scrip outlines five themes that have emerged during 2025 and in discussions at the recent Jefferies conference in London.

Lundbeck Concedes Avadel Bidding War, But Remains On The Hunt

 
• By Manas Mishra

Lundbeck does not plan to raise its offer for sleep specialist Avadel, clearing the way for Alkermes to win the two-way bidding war.